Every October, pink ribbons bring one question back into focus: when should you actually start getting mammograms, and how often? Breast Cancer Awareness Month 2026 arrives with genuine confusion on this point, because official guidance and headline-grabbing research are pulling in different directions. The U.S. Preventive Services Task Force and the CDC both point to biennial screening starting at 40. At the same time, a wave of new research on blood-based genetic risk scores is testing whether screening could someday be tailored to your personal risk rather than your birthday alone.
Here is what the current guidelines actually say, where risk factors like family history change the picture, what the emerging blood test research does and does not show yet, and a practical path for deciding what to do this month.
What the current guidelines actually recommend
For women at average risk, the two major U.S. bodies agree on the basics. The U.S. Preventive Services Task Force gives a Grade B recommendation for biennial (every two years) screening mammography between ages 40 and 74. The CDC states the same age-and-frequency window for women at average risk. Neither is a lifetime prescription: both frame it as the starting point for a conversation with a clinician, not a one-size rule.
The age-75-and-older gap
For women 75 and older, the USPSTF says the evidence is currently insufficient to recommend for or against continued screening. That is not the same as saying screening is unnecessary; it means the research base to weigh benefits against harms (including overdiagnosis) at that age is thinner. This is a conversation to have directly with a clinician, factoring in overall health and life expectancy.
What “average risk” is assumed to mean
These default guidelines assume no first-degree relative with breast cancer, no known high-risk genetic variant, and no personal history of breast disease. If any of those apply to you, the standard 40-to-74 framework is a floor, not the full picture.
When your risk profile changes the timeline
Family history is the risk factor guidelines address most directly. A first-degree relative (parent, sibling, or child) with breast cancer is enough to justify discussing earlier or more frequent screening with a doctor. Dense breast tissue, found on a prior mammogram, is another factor that can shift the conversation toward supplemental imaging like ultrasound or MRI.
BRCA1, BRCA2, and genetic counseling
Inherited mutations in the BRCA1 or BRCA2 genes carry a substantially higher lifetime risk, and current guidance treats this as its own track: separate genetic counseling and testing recommendations apply, distinct from routine population screening. A blood-based genetic test can identify a BRCA mutation, but the decision to test is meant to follow a conversation about family history and personal risk, not a standalone purchase.
The blood test on the horizon: polygenic risk scores
Beyond single-gene mutations like BRCA, researchers have been building polygenic risk scores (PRS): a laboratory analysis that combines hundreds of common genetic variants, each with a tiny individual effect, into one composite risk estimate from a blood sample. The idea is to catch the much larger group of people whose elevated risk comes from many small genetic nudges rather than one dramatic mutation.
A study highlighted by the American Association for Cancer Research illustrates where this research currently stands. Investigators applied a 313-variant polygenic risk score to women already diagnosed with early, non-invasive breast abnormalities (ductal or lobular carcinoma in situ) and found that those with a higher score were more likely to later receive a breast cancer diagnosis. In plain terms: among people who already had an early abnormal finding, the blood-based score helped separate those at higher versus lower risk of progression.
What this means for you right now
This is genuinely useful science, and also genuinely not ready to replace anything. The study was retrospective, applied to a specific population (people with an existing abnormal finding, not the general public), and the announcement itself did not report the kind of large-scale, prospective validation that would be needed before any medical body could recommend it for routine use. The USPSTF has explicitly stated it found no evidence yet on the benefits or harms of individualizing screening based on risk scores. Translation: interesting, promising, not actionable at your next checkup — yet.
A practical way to think about your own timeline
Rather than waiting for a single number to resolve the guideline debate, most clinicians use a layered approach: standard guidelines as the floor, personal and family history as the adjustment, and any lab or genetic results you already have as additional context.
| Din situation | What guidelines suggest | Next step |
|---|---|---|
| Average risk, no family history, ages 40-74 | Mammogram every 2 years | Schedule routine screening |
| First-degree relative with breast cancer | Possible earlier start, closer follow-up | Discuss timing with your doctor |
| Known or suspected BRCA1/BRCA2 in the family | Separate genetic counseling pathway | Ask for a referral to genetic counseling |
| Dense breast tissue noted on a prior mammogram | Possible supplemental imaging | Ask whether ultrasound or MRI adds value for you |
| Age 75 or older | Evidence currently insufficient either way | Weigh continued screening individually with your doctor |
When to see a doctor sooner rather than later
- A new lump, thickening, or persistent change in breast shape, regardless of your age or last mammogram date.
- Nipple discharge, skin dimpling, or unexplained skin changes over the breast.
- A recent addition to your family history (a parent, sibling, or child newly diagnosed).
- Genetic testing elsewhere in the family that revealed a BRCA1 or BRCA2 variant.
None of these symptoms mean cancer is present, but any of them is a reason to move up your next conversation with a clinician rather than waiting for your next scheduled mammogram.
Ordlista
Polygenic risk score (PRS): a single risk estimate calculated from many common genetic variants, each contributing a small effect, combined into one number from a blood or saliva sample.
BRCA1 / BRCA2: two genes that, when carrying certain inherited mutations, substantially raise lifetime breast and ovarian cancer risk.
Ductal carcinoma in situ (DCIS): abnormal cells confined to the milk ducts, considered a very early, non-invasive finding.
Biennial screening: a screening test performed once every two years.
Vanliga frågor
What age should I start getting mammograms?
For average-risk women, the USPSTF and CDC both point to age 40 as the starting point, with screening every two years through age 74. If you have a first-degree relative with breast cancer or a known genetic risk factor, ask your doctor whether starting earlier makes sense for you.
How often should I get a mammogram after 50?
Current U.S. guidelines recommend every two years for average-risk women between 40 and 74, including the 50s and 60s. Some clinicians recommend annual screening for higher-risk individuals; this is worth a direct conversation rather than assuming either interval applies to you.
Is there a blood test that predicts breast cancer risk?
Polygenic risk score blood tests exist in research settings and are showing promising associations with future risk in specific populations. They are not yet validated for routine, general-population use, and no major guideline body currently recommends them as a substitute for mammography.
Does a normal mammogram mean I don’t need to worry about family history?
No. A normal result reflects that screening moment only. Family history is a separate, ongoing factor that can change how often you’re screened and whether additional tests or genetic counseling are appropriate, regardless of past results.
What happens after age 75?
The USPSTF currently states the evidence is insufficient to recommend for or against continued screening past 75. This is an individual decision best made with a clinician, considering overall health and personal preferences.
Källor
- U.S. Preventive Services Task Force — Breast Cancer Screening recommendation
- CDC — Breast Cancer Screening
- MedlinePlus — Mammography
- American Association for Cancer Research — polygenic risk score study announcement
Related reading
Utforska vår comprehensive breast cancer guide covering symptoms, diagnosis, and treatment options for a fuller picture of the disease beyond screening timing.
Läs vår coverage of blood-based ctDNA testing for breast cancer recurrence monitoring, a different lab tool used once a diagnosis is already known.
Understand what your own results mean
Whatever your screening timeline turns out to be, the lab results that follow — from a routine panel to a specialist referral — are easier to act on when you understand them. Förstå dina labresultat med AI DiagMe.
